Browsing Tag
Epicrispr Biotechnologies
1 post
Facioscapulohumeral muscular dystrophy market is set to expand through 2034 with gene therapy innovation and FDA acceleration
Facioscapulohumeral muscular dystrophy market to expand across 7MM by 2034, driven by gene therapy, rising diagnosis, and key drug launches from Roche, Avidity, and Epicrispr.